Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January
January 04 2021 - 8:00AM
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage,
biopharmaceutical company dedicated to developing and
commercializing first-in-class, oral enzyme therapeutics to treat
patients with rare and severe metabolic and kidney disorders, today
announced that company management will participate in two upcoming
investor conferences in January:
H.C. Wainwright Bioconnect 2021 Conference
- Louis Brenner, M.D., Allena’s President and Chief Executive
Officer, will participate in a pre-recorded fireside chat, which
will become available for on-demand viewing at 6:00 a.m. ET on
Monday, January 11, 2021.
15th Annual Stern IR
Corporate Access Event
- Louis Brenner, M.D., Allena’s President and Chief Executive
Officer, will pre-record a corporate overview, which will become
available for on-demand viewing at 7:00 a.m. ET on Monday, January
11, 2021. Management will also be available for one-on-one meetings
from Monday, January 11-Thursday, January 14, 2021.
The presentations will be available for on-demand viewing under
“Events and Presentations” in the Investors section of the
Company’s website at www.allenapharma.com. Replays of the
webcasts will be available on the Allena website for approximately
30 days.
About Allena PharmaceuticalsAllena
Pharmaceuticals, Inc. is a late-stage biopharmaceutical
company dedicated to developing and commercializing first-in-class,
oral enzyme therapeutics to treat patients with rare and severe
metabolic and kidney disorders. Allena’s lead product candidate,
reloxaliase, is currently being evaluated in a pivotal Phase 3
clinical program for the treatment of enteric hyperoxaluria, a
metabolic disorder characterized by markedly elevated urinary
oxalate levels and commonly associated with kidney stones, chronic
kidney disease and other serious kidney disorders. Allena is also
developing ALLN-346 for the treatment of hyperuricemia in the
setting of gout and advanced chronic kidney disease, with Phase 1b
multiple-ascending dose and Phase 2 proof-of-concept studies
planned for 2021.
Investor ContactHannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media ContactAdam DaleyBerry & Company
Public Relations 212-253-8881adaley@berrypr.com
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Apr 2023 to Apr 2024